[1]马丽,李红.粪菌移植在代谢综合征治疗中的研究现况[J].国际内分泌代谢杂志,2021,41(04):300-303.[doi:10.3760/cma.j.cn121383-20200610-06029]
　Ma Li,Li Hong..Current status of research on fecal bacteria transplantation in the treatment of metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2021,41(04):300-303.[doi:10.3760/cma.j.cn121383-20200610-06029]
点击复制

粪菌移植在代谢综合征治疗中的研究现况()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年04期
页码:
300-303
栏目:
肠道内分泌与代谢性疾病专题
出版日期:
2021-07-20

文章信息/Info

Title:
Current status of research on fecal bacteria transplantation in the treatment of metabolic syndrome
作者:
马丽; 李红
贵州医科大学附属医院内分泌与代谢病科,贵阳 550001
Author(s):
Ma Li;  Li Hong.
Department of Endocrinology and Metabolism, Affifiliated Hospital of Guizhou Medical University, Guiyang 550001, China
关键词:
代谢综合征(MS)是以肥胖、脂代谢异常、糖代谢异常及高血压等为特征的临床综合征。近年来; 随着生活水平的提高; 生活方式的改变; MS的发生风险逐渐升高。因此; 防治MS是当今社会的重要课题之一。肠道微生物是一个庞大的微生物群; 维持着机体重要的生理功能; 肠道微生物的失调不仅与胃肠道功能紊乱相关; 而且与机体的代谢紊乱有关。粪菌移植(FMT)可用于调节肠道微生物的平衡; 目前已用于治疗MS。但如今; 我国在FMT过程、肠道微生物参与MS的可能机制及FMT用于治疗MS的研究较为薄弱; 因此; 应进一步对相关的研究进行深入的挖掘和整理。
Keywords:
Gut microbiota;  Metabolic syndrome;  Fecal microbiota transplant
DOI:
10.3760/cma.j.cn121383-20200610-06029
摘要:
代谢综合征(MS)是以肥胖、脂代谢异常、糖代谢异常及高血压等为特征的临床综合征。近年来,随着生活水平的提高,生活方式的改变,MS的发生风险逐渐升高。因此,防治MS是当今社会的重要课题之一。肠道微生物是一个庞大的微生物群,维持着机体重要的生理功能,肠道微生物的失调不仅与胃肠道功能紊乱相关,而且与机体的代谢紊乱有关。粪菌移植(FMT)可用于调节肠道微生物的平衡,目前已用于治疗MS。但如今,我国在FMT过程、肠道微生物参与MS的可能机制及FMT用于治疗MS的研究较为薄弱,因此,应进一步对相关的研究进行深入的挖掘和整理。
Abstract:
Metabolic syndrome(MS)is a clinical syndrome characterized by obesity, abnormal lipid metabolism, abnormal glucose metabolism, and hypertension. In recent years, with the continuous improvement of living standards and the continuous changes in lifestyle, the risk of developing into MS is gradually increasing. Therefore, the prevention and treatment of MS is one of the important topics today. Gut microbes is a huge microbiome, which maintains the important physiological function of the body. Gut microbial disorders are not only related to gastrointestinal dysfunction, but also to the metabolic disorders of the body. Fecal microbiota transplant(FMT)can be used to regulate the balance of gut microbes and is currently used to treat MS. However, nowadays, the process of FMT, the mechanism that gut microbiota lead to MS and the research on the treatment for MS with FMT are relative immature in China. Therefore, the relevant research about FMT should be further excavated and organized.

参考文献/References:

[1] Guo Y,Musani SK,Sims M,et al. Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes:the Atherosclerosis Risk in Communities Study and Jackson Heart Study[J].Diabetol Metab Syndr,2018,10(1):42.DOI:10.1186/s13098-018-0344-3.
[2] Neish AS.Microbes in gastrointestinal health and disease[J].Gastroenterology,2009,136(1):65-80.DOI:10.1053/j.gastro.2008.10.080.
[3] Vrieze A,Van Nood E,Holleman F,et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].Gastroenterology,2012,143(4):913-916.e7.DOI:10.1053/j.gastro.2012.06.031.
[4] Bakken JS,Borody T,Brandt LJ,et al.Treating Clostridium diffificile infection with fecal microbiota transplantation[J].Clin Gastroenterol Hepatol,2011,9(12):1044-1049.DOI:10.1016/j.cgh.2011.08.014.
[5] Kassam Z,Dubois N,Ramakrishna B,et al.Donor screening for fecal microbiota transplantation[J].N Engl J Med,2019,381(21):2070-2072.DOI:10.1056/NEJMc1913670.
[6] Bibbò S,Settanni CR,Porcari S,et al.Fecal microbiota transplantation:screening and selection to choose the optimal donor[J].J Clin Med,2020,9(6):1757.DOI:10.3390/jcm9061757.
[7] Haifer C,Kelly CR,Paramsothy S,et al.Australian consensus statements for the regulation,production and use of fecal microbiota transplantation in clinical practice[J].Gut,2020,69(5):801-810.DOI:10.1136/gutjnl-2019-320260.
[8] Brown WR.fecal microbiota transplantation in treating clostridium diffcile infection [J].J Dig Dis,2014,15(8):405-408.DOI:10.1111/1751-2980.12160.
[9] Gough E,Shaikh H,Manges AR.Systematic review of intestinal microbiota transplantation(fecal bacteriotherapy)for recurrent Clostridium diffificile infection[J].Clin Infect Dis,2011,53(10):994-1002.DOI:10.1093/cid/cir632.
[10] Burz SD,Abraham AL,Fonseca F,et al.A guide for Ex Vivo handling and storage of stool samples intended for fecal microbiota transplantation[J].Sci Rep,2019,9(1):8897.DOI:10.1038/s41598-019-45173-4.
[11] Kassam Z,Lee CH,Yuan Y,et al.Fecal microbiota transplantation for Clostridium difficile infection:systematic review and meta-analysis[J].Am J Gastroenterol,2013,108(4):500-508.DOI:10.1038/ajg.2013.59.
[12] Allegretti JR,Kassam Z,Osman M,et al.The 5D framework:a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection[J].Gastrointest Endosc,2018,87(1):18-29.DOI:10.1016/j.gie.2017.05.036.
[13] Kao D,Roach B,Silva M,et al.Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection:a randomized clinical trial[J].JAMA,2017,318(20):1985-1993.DOI:10.1001/jama.2017.17077.
[14] Quraishi MN,Widlak M,Bhala N,et al.Systematic review with meta-analysis:the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection[J].Aliment Pharmacol Ther,2017,46(5):479-493.DOI:10.1111/apt.14201.
[15] DeFilipp Z,Bloom P,Torres Soto M,et al.Drug resistant E.coli bacteraemia transmitted by fecal microbiota transplant[J].N Engl J Med,2019,381(21):2043-2050.DOI:10.1056/NEJMoa1910437.
[16] Le Chatelier E,Nielsen T,Qin J,et al.Richness of human gut microbiome correlates with metabolic markers[J].Nature,2013,500(7464):541-546.DOI:10.1038/nature12506.
[17] Jiao N,Baker SS,Nugent CA,et al.Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents:a meta-analysis[J].Physiol Genomics,2018,50(4):244-254.DOI:10.1152/physiolgenomics.00114.2017.
[18] De Clercq NC,Frissen MN,Groen AK,et al.Gut microbiota and the gut-brain axis:new insights in the pathophysiology of metabolic syndrome[J].Psychosom Med,2017,79(8):874-879.DOI:10.1097/PSY.0000000000000495.
[19] 贺文娟,钟燕.肠道菌群及其代谢产物与肥胖的关系[J].国际内分泌与代谢杂志,2018,1(38):40-43.DOI:10.3760/cma.j.issn.1673-4157.2018.01.011.
[20] Turnbaugh PJ,Hamady M,Yatsunenko T,et al.A core gut microbiome in obese and lean twins[J].Nature,2009,457(7228):480-484.DOI:10.1038/nature07540.
[21] Allegretti JR,Kassam Z,Mullish BH,et al.Effects of fecal microbiota transplantation with oral capsules in obese patients[J].Clin Gastroenterol Hepatol,2020,18(4):855-863.e2.DOI:10.1016/j.cgh.2019.07.006.
[22] Yang T,Santisteban MM,Rodriguez V,et al.Gut dysbiosis is linked to hypertension[J].Hypertension,2015,65(6):1331-1340.DOI:10.1161/HYPERTENSIONAHA.115.05315.
[23] Li J,Zhao F,Wang Y,et al.Gut microbiota dysbiosis contributes to the development of hypertension[J].Microbiome,2017,5(1):14.DOI:10.1186/s40168-016-0222-x.
[24] 郭上齐,武华,翟春宝,等.粪菌移植对营养性肥胖大鼠血脂及肠道屏障的影响[J].中国现代医生,2016,054(004):25-27,33,封3.
[25] Le Roy T,Lécuyer E,Chassaing B,et al.The intestinal microbiota regulates host cholesterol homeostasis[J].BMC Biol,2019,17(1):94.DOI:10.1186/s12915-019-0715-8.
[26] Di Luccia B,Crescenzo R,Mazzoli A,et al.Rescue of fructose-induced metabolic syndrome by antibiotics or faecal transplantation in a rat model of obesity[J].PLoS One,2015,10(8):e0134893.DOI:10.1371/journal.pone.0134893.
[27] Kootte RS,Levin E,Salojarvi J,et al.Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition[J].Cell Metab,2017,26(4):611-619.e6.DOI:10.1016/j.cmet.2017.09.008.

备注/Memo

备注/Memo:
基金项目:国家重点研发计划(2017YFC1310700)
通信作者:李红,Email: lee-helen@sohu.com
更新日期/Last Update: 1900-01-01